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Meagan Elizabeth Giles, B.S.

Thesis Chair: Blair K. Stevens, MS, CGC

Performing non-invasive prenatal testing (NIPT) on a pregnant woman with a
chromosomally abnormal neoplasm may incidentally lead to the diagnosis of cancer due to the
coexistence of circulating tumor and placental DNA. Published information regarding NIPT’s
accuracy for neoplasm screening is limited, and guidance for patient management is currently
lacking. This challenges clinicians’ ability to counsel patients regarding the implications of
these results, which often is the responsibility of a genetic counselor. Over three hundred
board-eligible/certified genetic counselors were surveyed regarding their awareness,
preferences, and attitudes towards NIPT’s ability to indicate maternal neoplasms. Despite 95%
of this cohort being aware of this possibility and 77% reporting that they would disclose these
results if indicated, only 29% routinely communicate this possibility to their patients in a pretest setting. Management recommendations that were made by counselors were highly variable,
and over half stated that they would feel uncomfortable or very uncomfortable counseling a
patient with these results. While less than half of counselors believed that the current benefits
of NIPT’s neoplasm screening ability outweigh its potential harms, 80% recognized it would be
beneficial in the future. A vast majority of counselors in this cohort felt institutional or national
guidelines were needed regarding the management of patients with NIPT results indicating
maternal neoplasms.
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INTRODUCTION
Cell-free DNA (cfDNA) was first identified in 1947 as fragments of nucleic acids
circulating in the blood of healthy individuals [1]. Since this initial discovery, circulating
cfDNA has been found to originate from two additional sources: tumor cells of cancer patients
[2], and placental cells of pregnant women [3]. These landmark discoveries have become the
basis of various diagnostic and screening technologies for both the fields of oncology and
obstetrics.
Cell-free DNA is found in the plasma of cancer patients in higher quantities compared
to individuals without cancer, the concentration of which has been shown to inversely correlate
with prognosis and decrease in response to successful treatment [2]. These cfDNA fragments
are believed to originate from the cancer cells of a tumor and represent the genetic makeup of
the malignancy, which often has genetic mutations or aberrant chromosome complements [4,
5]. Circulating tumor DNA (ctDNA) has been the object of interest for cancer research and
clinical test developers, as it has been proposed that specific ctDNA biomarkers may be
identified for tumors that cannot be directly or routinely biopsied. Analysis of ctDNA, also
referred to as a “liquid biopsy,” may be used to eliminate the need for invasive, painful, and
costly procedures, and can be used to gauge tumor evolution and the development of resistance
to therapy over time [4]. A 2014 study by Bettegowda et al. [6] found detectable levels of
ctDNA in patients with metastatic and localized cancers of all stages, as well as in cases where
cancer had not yet been detected with standard imaging, indicating a possible mechanism of
early cancer detection. In their blinded study, Bettegowda et al. attempted to establish the
sensitivity and specificity of the “liquid biopsy” by analyzing KRAS mutations in primary
tumors of 206 metastatic colorectal cancer patients compared against KRAS mutations
identified in the patient’s plasma, which yielded a sensitivity of 87.2% and a specificity of
1

99.2%. While clinical laboratories have already begun to offer “liquid biopsies” as a screening
method to patients at risk for cancer [7], the sensitivity and specificity of ctDNA for early
cancer detection remains largely undefined. Even if this noninvasive method is proven to be
accurate, it does not yet directly indicate from where in the body the ctDNA is originating.
Additionally, a biopsy of the primary tumor is still needed in order to determine if it is
malignant or benign in nature, and to assess its degree of potential metastasis [6].
Similarly, aneuploidy screening through Noninvasive Prenatal Testing (NIPT) analyzes
circulating cfDNA from placental cells that are found at an average concentration of
approximately 10% in maternal serum during pregnancy [8]. NIPT avoids the risk of
miscarriage associated with prenatal diagnostic procedures and is a highly sensitive screen for
specific chromosome conditions [9]. A meta-analysis by Gil et al. [10] examined 37 relevant
studies to assess the performance of NIPT in screening for aneuploidies. The study reported the
sensitivity to be greater than 99% for trisomy 21, 96% for trisomy 18, and 91% for trisomy 13
with false positive rates of < 0.1%, 0.13%, and 0.13%, respectively. Known explanations for
false positive results, or results discordant between NIPT and fetal karyotype, include statistical
error, vanishing twin/co-twin demise, placental, fetal, and/or maternal mosaicism, undiagnosed
maternal aneuploidy, copy number variants (CNVs), and abnormal chromosome compliment
relating to maternal neoplasms [9, 11].
Malignant tumors are found in about 1 in 1000 pregnant women, and benign neoplasms
of many types, such as uterine leiomyomas, are also observed [12]. The most common cancers
diagnosed during pregnancy are associated with those found in women of reproductive age—
breast and cervical cancer, leukemia, and lymphoma make up over 75% of reported cases [12].
The massively parallel shotgun sequencing (MPSS) technology utilized by some NIPT
companies is able to assess genomic gains and losses across several chromosomes but cannot
2

make the distinction between cell-free fragments originating from different tissue sources.
Therefore, since many malignancies are chromosomally unstable [5], the coexistence of
circulating tumor cfDNA and placental cfDNA may incidentally lead to abnormal NIPT results
that raise a suspicion for cancer in pregnant women who have NIPT performed for aneuploidy
screening, as the results generated in these scenarios (monosomies or multiple aneuploidies) are
often not compatible with life or reflect fetal findings [13-15].
Published information regarding NIPT’s neoplasm screening ability, intentional or
incidental, is limited. Osborne et al. published the first case of maternal cancer that was
diagnosed following discordant NIPT results in 2013. The patient’s NIPT results were positive
for both trisomy 13 and monosomy 18, and were confirmed on repeat NIPT samples at various
points throughout the pregnancy. However, fetal anatomy, karyotype, and placental biopsy
were normal. Following delivery, the patient experienced significant pelvic pain and was
diagnosed with high-grade neuroendocrine sarcoma, with 80% of the examined cells
demonstrating the previously observed aneuploidies [16]. Subsequently, two NIPT laboratories
presented abstracts that reported cases of maternal cancers incidentally indicated by NIPT at
the 2015 ACMG Annual Clinical Genetics Meeting [17, 18]. One report described two cases of
multiple genomic gains or losses, one of which led to a diagnosis of invasive grade 2 breast
cancer. A malignancy was not found in the other patient [17]. The second abstract reported
seven confirmed, separate cases of maternal malignancy out of 37 NIPT results that detected
multiple aneuploidies [18]. Bianchi et al. (2015) published a retrospective study of pregnant
women who had an abnormal NIPT result involving chromosomes 21, 18, 13, X, and Y, and
were subsequently diagnosed with cancer. This study included the previously described cases.
This report found that out of 125,426 NIPT tests, 3,757 were abnormal for one or more
aneuploidies. Out of this group, 10 women were reported to have been diagnosed with cancer
3

following their prenatal testing. Seven of these 10 cases screened positive for multiple
aneuploidies. Diagnoses included lymphoma, leukemia, colorectal, anal, and neuroendocrine
cancers. Upon further inspection of these cases, chromosomal aberrations were found spanning
the entire genome. Even though follow-up for both normal and abnormal results was
significantly limited, the risk for cancer when multiple aneuploidies were detected and fetal
karyotype was normal was estimated to be 20 – 44% [19]. Later, Snyder et al. (2016) sought to
determine the etiology of monosomy or multiple aneuploidies by conducting a retrospective
analysis of patient follow-up and concluded that there are multiple causes for these results,
either maternal, fetal, and placental in nature [20]. Uterine leiomyomas (fibroids) with an
abnormal chromosome compliment have also been reported and can confound NIPT results
[21, 22]. Given that 40-60% of women are reported to have uterine fibroids by age 35 [23], this
is yet another factor to consider in the face of abnormal NIPT results.
Ethical concerns as well as associated practical and legal considerations raised by
incidental findings are not unique to NIPT. However, with respect to NIPT results indicative of
maternal neoplasms, it is not clear what, if any, follow-up clinical evaluation is appropriate and
little direction is available to help guide management and counseling. Yet, as of March 2016,
laboratories performing NIPT via MPSS are either reporting results concerning for maternal
neoplasm verbally to the ordering provider without documentation of these results on their
reports, or are reporting results as multiple fetal aneuploidies that cannot feasibly reflect fetal
findings. Recommendations have been proposed that pre-test NIPT counseling should include a
statement about the possibility of incidental findings, whether they be maternal or fetal in
nature [24], yet recommendations regarding post-test counseling and work-up in cases
indicative of maternal malignancy are lacking and many clinicians, including genetic
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counselors, may not be adequately equipped to counsel patients about these implications in the
post-test setting.
While results indicative of maternal malignancies are still rarely encountered, the
number of women being tested via NIPT has increased with the expansion of its use from
“high-risk populations” – women at an increased risk for a fetus with aneuploidy – to the
general population, meaning the number of incidental findings is likely to increase as more
women undergo NIPT.
Prenatal or laboratory genetic counselors are often the ones involved in communicating
NIPT results to patients or providers, particularly when they are abnormal. However, genetic
counselors of all specialties may have a role in the management of NIPT results indicative of
maternal neoplasms. Prenatal genetic counselors are often responsible for NIPT pre-test
counseling, or are consulted to counsel patients post-test when abnormal NIPT results arise.
Pediatric genetic counselors may aid in facilitating confirmatory testing of the baby at birth,
and cancer genetic counselors may be sent referrals when ordering physicians are told by lab
directors or lab genetic counselors that results may have a malignant etiology. Genetic
counselors are known to specialize in communicating this information to patients and making
appropriate recommendations for care. This study thus aims to assess genetic counselors’
awareness of NIPT’s ability to detect maternal neoplasms, how this may or may not affect pretest NIPT counseling, how counselors prefer for non-validated incidental findings of maternal
neoplasms to be reported and managed, and their attitudes regarding NIPT’s neoplasm
screening ability.

5

METHODS
Participants for this study were recruited via the National Society of Genetic Counselors
(NSGC) and included English-speaking board-eligible or board-certified genetic counselors of
all specialties. Members who agreed to participate were asked to complete an anonymous
online survey after providing informed consent. The survey was split into two arms based on
the participant’s specialty of practice. Genetic counselors who indicated that they practiced in
the prenatal setting, either exclusively or in combination with other specialties, completed the
Prenatal Arm. Genetic counselors who indicated that they practiced in any other combination of
specialties that did not include prenatal genetic counseling completed the Non-Prenatal Arm.
The Prenatal Arm consisted of six sections with multiple choice questions and the opportunity
to provide additional comments. The Non-Prenatal Arm was identical to the Prenatal Arm with
the exception of the sections aimed at analyzing prenatal genetic counselors’ pre-test
counseling strategies for NIPT (see appendix for survey questions). The survey was uniquely
developed for the purpose of this study, and thus did not utilize any formal validated measures.
Participants were incentivized to complete the study with the opportunity to win one of two
available gift cards by providing email addresses that were not linked to their survey.
Responses were collected for a one-month period between September and October of 2015.
Study data were collected and managed using REDCap electronic data capture tools hosted at
The University of Texas Health Science Center at Houston [25]. REDCap (Research
Electronic Data Capture) is a secure, web-based application designed to support data capture
for research studies. STATA statistical software was used to analyze data. The study was
approved by the institutional review board at the University of Texas Health Science Center
(HSC-MS-15-0442).

6

Statistical Analysis
Statistically significant relationships were determined after analyzing comparison
groups either with Pearson 2 or Fisher’s exact test. Comparison groups primarily focused on
those practicing within particular specialties, and those who have had personal experience
counseling about NIPT’s ability to indicate maternal neoplasms. A p-value of < 0.05 was
considered significant.
RESULTS
Demographics
A total of 367 participants responded to the survey, representing a response rate of
approximately 13% of the NSGC membership at the time the survey was distributed. Twenty
four participants were excluded from the study due to incomplete survey responses, leaving a
final sample size of 343, for which 168 (49%) completed the Prenatal Arm, and 175 (51%)
completed the Non-Prenatal Arm. The specialties of the 175 participants in the Non-Prenatal
Arm included cancer, lab/industry, pediatrics/medical genetics, and a range of sub-specialties
such as neurology, cardiology, pharmacogenetics, and psychiatric genetics.
The majority of participants indicated that they had 5 years or less of total experience
practicing as a genetic counselor (59.8%, 205/343), as well as within their current specialty
(69.4%, 238/343). The most common place of practice was a university medical center (42.3%,
145/343) or private hospital/medical facility (24.8%, 85/343). Genetic counselors were
ascertained from across the country, with a majority of participants practicing in the Midwest
(27.4%, 94/343). Eighty-seven percent of genetic counselors (298/343) reported that they were
currently seeing patients, and 60% (206/343) indicated that they were currently discussing
NIPT with either patients or providers. In order to assess for external validity, demographic
7

information of the dataset was compared against the 2014 National Society of Genetic
Counselors Professional Status Survey (PSS); the sample population was found to be
appropriately representative. Additionally, there were no statistically significant differences for
any factors between the Prenatal and Other Arms (p > 0.05). A complete list of participant
characteristics are described in Table 1.
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Table 1
Participant demographics (n = 343)
Variable
n
Total Years Experience
0 – 5 years
205
6 – 10 years
58
11 – 15 years
36
16 – 20 years
18
> 20 years
26
Total Years Experience in specialty
0 – 5 years
238
6 – 10 years
45
11 – 15 years
30
16 – 20 years
12
> 20 years
18
Institution Type
University medical center
145
Private hospital/medical facility
85
Public hospital/medical facility
59
Physician’s private practice
25
Commercial laboratory
34
Other
14
Two or more institution types
19
Region
Northeast
50
Mid-Atlantic
42
Southeast
43
Southwest
53
Midwest
94
West
30
Northwest
16
Other
15
Currently seeing patients
Yes
298
No
45
Currently counseling about NIPT
Yes
206
No
137

%
59.8
16.9
10.5
5.3
7.6
69.4
13.1
8.8
3.5
5.3
42.3
24.8
17.2
7.3
9.9
4.1
5.5
14.6
12.2
12.5
15.5
27.4
8.8
4.7
4.4
86.9
13.1
60.1
39.9

Awareness
As seen in Table 2, a majority of genetic counselors surveyed (95%, 326/343) reported
they were previously aware of NIPT’s ability to indicate maternal neoplasms, with most having
first learned of it through a professional conference, peer-reviewed journal, or discussion
forum. Thirty (20 Prenatal Arm, 10 Non-Prenatal Arm) reported that they first learned about
this possibility by encountering this case in their own personal experience.
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Awareness of NIPT’s ability to indicate maternal neoplasms, n (%)
Prenatal
Non-Prenatal
Total
Source
n = 168
n = 175
n = 343
Professional conference, journal, discussion forum
96 (57.1)
104 (59.4)
200 (58.3)
Colleague
31 (18.5)
35 (20.0)
66 (19.2)
Personal experience
20 (11.9)
10 (5.7)
30 (8.7)
Popular media
8 (4.8)
3 (1.7)
11 (3.2)
I was not previously aware
7 (4.2)
10 (5.7)
17 (5.0)
Other
5 (3.0)
7 (4.0)
12 (3.5)
I do not recall
1 (0.6)
6 (3.4)
7 (2.0)
Table 2

Pre-test counseling for NIPT
Genetic counselors who completed the Prenatal Arm ranked how frequently various
pre-test counseling points were included when discussing NIPT for a routine indication such as
for advanced maternal age by using a Likert scale ranging from “always” to “never.” Figure 1
demonstrates the frequencies for each pre-test counseling point. Of note, counseling that NIPT
Figure 1

Frequencies of pre-test counseling discussion points for NIPT

Possibility of false negatives/positives
Accuracy of NIPT
Positive NIPT warrants diagnostic testing
NIPT can evalute for fetal sex
cfDNA originates from the placenta

NIPT may not yeild a result
Possible reasons for a false positive
Possibility of unexpected/rare results
Possible reasons for a false negative
0%
Always

Mostly

20%

Sometimes

40%
Rarely

60%

80%

100%

Never

results may indicate unexpected or rare conditions in the pregnancy or mother was “always”
discussed only 12.5% of the time, with 44.6% “rarely” or “never” mentioning this possibility.
Prenatal counselors who had personally experienced a case in which NIPT results indicated
maternal neoplasms were more likely to include this statement in their pre-test counseling (p =
10

0.028). There were no other statistical correlations found between inclusion of this statement
and other measured variables.
A majority (67.7%, 109/161) of counselors who completed the Prenatal Arm reported
that their pre-test counseling had not changed since becoming aware of the possibility that
NIPT could indicate maternal neoplasms, as illustrated in Table 3.
Table 3
Perceived changes in pre-test counseling for NIPT
Perceived change
n*
%
Yes, it has greatly changed

6

3.7

Yes, it has slightly changed

46

28.6

No, it has not changed

109

67.7

*Six participants who were not previously aware were not instructed to answer
this question (n = 161)

Counselors were more likely to report that their pre-test counseling had changed if they
had encountered this type of case in their own clinical experience (p < 0.001), or if they had
more years of experience overall (p = 0.003). However, general awareness of NIPT’s neoplasm
screening ability did not play a role in change of pre-test counseling (p = 0.154). Out of the 20
Prenatal Arm counselors who reported having personal experience, 11 further elaborated on
how their pre-test counseling has changed since this experience. Four stated that they will
explicitly discuss cancer as a possibility in every pre-test counseling session for NIPT, while 3
stated that they now vaguely allude to the possibility of detecting “maternal health factors.”
Three participants in this subgroup said they treat it on a case-by-case basis, and one reported
they no longer use an NIPT platform where this is a possibility. For the remaining 148 Prenatal
Arm counselors who did not have personal experience with this indication, 71 (48.0%)
participants chose to describe their changes, or lack of changes, to pre-test counseling, as
illustrated in Table 4.
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Table 4

Free responses: perceived changes in pre-test counseling (n = 71)
Yes, it has changed (n = 31)

Inclusion of vague statement (n = 17, 54.8%)
“I counsel that other chromosome changes may be identified that need further
clarification, but I do not specifically counsel that changes may reflect a
neoplasm/cancer.”
Always discuss (n = 5, 16.1%)
“I always, always, always incorporate this into my consent process now. I think it’s
extremely important that this testing can reveal more about Mom than we were
expecting, and I think it’s essential that the patient understands this.”
Case by case basis (n = 4, 12.9%)
“If the patient has a personal history/high risk of cancer or a strong family history of
cancer, I discuss the possibility that NIPT can occasionally detect cancers. The
information has not been incorporated into typical counseling sessions because of the
rarity of this type of result and the lack of data available on likelihoods, outcomes,
etc.”
Added to consent form (n = 3, 9.7%)
“We have added a short part to our verbal consent that states that some results may
tell us information about the patient’s health and could require follow-up testing.”
Other (n = 2, 6.5%)
No, it has not changed (n = 40)
Don’t discuss (n = 26, 65.0%)
“Still a lot of unknowns at this point. As a practice, we have decided not to change
things yet.”
“With many types of prenatal genetic screening (ultrasound, traditional maternal
serum screening, etc.) there is a possibility of incidentally obtaining information that
suggests increased risk of a maternal or fetal health condition unrelated to the primary
purpose of the screen. In my opinion, pre-test counseling would serve no useful
purpose and could lead patients to mistakenly believe that one of the roles of NIPT is
cancer screening.”
Previously aware (n = 4, 10.0%)
“I only started counseling patients after I learned of this.”
Use different lab (n =3, 7.5%)
“I do not counsel about uncovering possible maternal cancers because I am told by the
lab whose test we use that their technology isn’t going to pick that up.”
Other (n = 7, 17.5%)

12

Reporting preferences
Participants who completed the Prenatal Arm were asked to state whether or not they
would disclose NIPT results indicative of a maternal neoplasm to a patient or provider if results
were not explicitly documented on the report – as was the current practice at the time of this
survey – versus if they were clearly documented on the report. Of those who completed the
Prenatal Arm, 76.8% (129/168) indicated that they would disclose this information to a patient
even if it was not documented on the report. Twenty-one percent (36/168) indicated they were
unsure if they would disclose, and 1.8% (3/168) reported they would not disclose this
information in any capacity. One-hundred twenty six (75.0%) participants chose to provide
reasons for why they would disclose this to a patient or not. Commonly observed response
themes and accompanying examples are illustrated in Table 5.

Conversely, almost all

participants stated that they would disclose this to a patient if it were clearly documented on the
test report (99.4%); one individual indicated that he or she was “unsure.”
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Table 5

Free responses: choice to disclose if results were not documented (n = 126)
Yes, I would disclose (n = 116)

Ethical principles (n = 55, 47.4%)
“I likely would. I think it’s important to note that we don’t know how good the test is at
identifying neoplasms/cancer, and that it might not be the reason we’re seeing what
we’re seeing, but the patient has the right to know and investigate further.”
“I feel it would be unethical not to inform them to give them the chance to be checked
for malignancy.”
Significant health implications (n = 35, 30.2%)
“This has vital implications for the patient’s health and an appropriate work-up should
be performed.”
“I would rather subject the patient to possibly unnecessary worry and cancer
screenings than have her pass away from a potentially treatable cancer (or have a
more complex treatment course) if it had been found early because I mentioned it.”
Consult with provider first (n = 10, 8.6%)
“It would be discussed with the MFM first and we would decide how to best handle the
situation together.”
Other (n = 16, 13.8%)
“I would likely think that yes, I would; but I imagine that as an office, we would need to
make ourselves aware of the medical/legal aspects of informing a patient of an
essentially undocumented result. I can’t imagine NOT saying something, but I don’t
exactly know what I would say or what recommendations I would make.”
“Case-by-case basis. I would want to talk with the lab first. I would also want to
consider what could have made the data look that way – ie does the patient have
fibroids that could cause concern for cancer on NIPT?”
No, I would not disclose (n = 10)
No data/not validated/no guidelines (n = 6, 60.0%)
“I would have to discuss with my MFM team and our director first. Since there is no
guideline, it’s like we are looking in the dark without a flashlight. Plus, insurance
won’t cover the expensive MRI, CT, etc. based on an abnormal [NIPT] result because
there is so little data. I don’t’ want my patient to get stuck with a huge bill only to find
nothing and keep her up at night for the rest of her life.”
“No. The testing has not been validated to test for maternal neoplasm and the data is
sparse. There are no recommendations for following a patient in this scenario.”
Other (n = 4, 40.0%)
“Unless I have a report in writing from the performing lab, I have no basis to disclose
an incidental finding to the patient.”
“If I disclosed this information, then I am assuming personal liability for whether this
information is correct or not.”
14

Participants of both arms were asked if they believe the potential benefits of NIPT’s
neoplasm screening ability outweigh its potential risks both currently and in the future. They
were also asked if NIPT companies should report non-validated findings, such as for
neoplasms/cancer. Responses are recorded and discussed in the Attitudes section below.
Counselors in the Prenatal Arm were more likely to disclose this information in the absence of
documentation if they believed that both currently, and in the future, the benefits of NIPT’s
ability to indicate maternal neoplasms outweigh the potential harms (p < 0.001 and p = 0.027,
respectively). Counselors who were more likely to withhold this information believed that
NIPT companies should not report non-validated findings (p < 0.001). There were no
significant differences in choice to disclose between those who had personal experience
counseling this type of case versus those who did not (p = 0.489).
All participants (Prenatal and Non-Prenatal Arms) were asked for their opinion
regarding the reporting of incidental findings of maternal neoplasms. A significant majority
(69.1%) believed that findings should be discussed by a lab director as well as documented on
the report. A smaller number (12.5%) believed that findings should continue to be discussed
by a lab director, but not documented on the report. Three percent of participants felt that
findings should not be reported in any capacity, whereas 12.8% were unsure. For those who
elaborated on their answers (n = 193), commonly observed response themes and accompanying
examples are listed in Table 6.
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Table 6 Free responses: preferences for maternal neoplasm results reporting (n = 113)
Documentation
“Potentially clinically relevant findings shouldn’t be excluded from the report. Relying
only on direct communication could result in miscommunication if multiple providers
are involved (OB, MFM, primary care, etc.).”
“It is extremely frustrating for legal and ethical reasons for findings to be disclosed to
a medical provider and yet not included on the report.”
Justification for referrals
“Documentation of increased risk is important for insurance coverage regarding
cancer screening.”
“Labs should always be willing to document any reports they are providing. In
addition, if insurance coverage of follow-up is ever an issue, documentation of an
initial, initiating event would be pretty much essential.”
Discussion
“I feel like it should not be included on the report because NIPT is not designed to pick
it up, and we do not yet know what the performance is like for detection of maternal
cancer (PPV, follow-up recommendations ,etc.). However, I do feel that the lab
director should ALWAYS call the ordering provider when these results are found, since
the follow-up should be on a case-by-case basis.”
“It depends on how reliable the results are – I see no issues in discussion with a GC
(aside from the usual concerns about how much patients remember what we tell them,
etc.), but inclusion on a report can sometimes lead providers to think ‘definitely’ when
the scenario is ‘possible.’”
Incidental findings are common
“They are incidental findings, not exactly the same but similar to the ones we
encounter with WES. These NIPT findings shouldn’t be ignored any more than the WES
incidental findings. However, the ability to screen for them should be validated first
and guidelines need to be established so GCs know where to refer patients once these
abnormal results are reported.”
“It is a medically actionable finding. It was not a part of the initial consent but 1) it
should be, and 2) if a lung tumor is picked up by a lung x-ray for pneumonia, it is still
reported.”
Opt in or out
“There should be an opt out option on the form for individuals to select whether or not
they would like to receive any incidental findings.”
Results should not be reported
“Technically we consent for NIPT as a test that gives information about the baby, not
the mom.”
“NIPT has not been validated for this purpose and laboratories should not offer
information that they cannot include on a report.”
“I don’t think we have enough data, at this time, to know what percentage of double
aneuploidies or aberrant results actually end up being diagnosed as maternal cancer. I
feel that if more data emerges and shows that the majority of the time it is maternal
neoplasm, then we can put it on the report without causing undue fear and anxiety. If it
is a minority of cases, I don’t know if having that on a report would have some sort of
potential insurance implications for that person as a ‘risk for cancer’ was diagnosed.”
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Individuals who reported personal experience with this type of case were more likely to
feel that results should be discussed AND documented (p = 0.024). Additionally, those who
believed that both the current and future benefits of NIPT’s ability to indicate maternal
neoplasms outweigh the harms were more likely to believe that findings should be discussed
AND documented (p < 0.001 for both factors).
All participants were asked who they believe should decide as to whether NIPT
incidental findings of maternal neoplasms/cancer are reported (select all that apply). Responses
are summarized in Figure 2. This was not influenced by the counselors’ area of practice, as
those who reported practicing in a lab or industry setting were not more likely to feel that
performing labs should be involved in this decision (p = 0.450).

Figure 2

Who should decide if NIPT neoplasm results are reported? (n = 628)
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Counseling strategies
A majority of counselors who completed the Prenatal Arm (51.8%) reported that they
would feel either uncomfortable or very uncomfortable counseling this type of indication.
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Counselors were more likely to feel comfortable counseling these cases had they already
encountered one in their personal experience (p < 0.001). Conversely, counselors were more
likely to feel uncomfortable if they believed that the benefits of NIPT’s ability to indicate
maternal neoplasms do not currently outweigh the harms (p < 0.001), and that NIPT companies
should not report non-validated findings (p = 0.009).
When asked what further recommendations, options, or referrals would be made when
counseling a case for which NIPT results indicate a maternal neoplasm, counselors were asked
to choose all that apply from several selections. Eighty-six percent of participants felt that more
than one recommendation or referral was appropriate, with an average of 3 selections per
participant. Twenty-five percent of participants indicated they were unsure about what
recommendations or referrals they would make in this setting. The number of selections is
depicted in Figure 3. Of note, “other” recommendations included offering whole-body MRIs or
referrals to cancer genetic counselors.

Figure 3
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The subgroup who reported personal experience with this indication recommended
equally diverse follow-ups, with a nine of the available eleven options being selected at least
once (n = 79). Counselors in this subgroup were more likely to suggest a referral to oncology (p
= 0.004), recommend performing a traditional screen (p = 0.044), or an invasive test (p =
0.001). However, counselors with personal experience were less likely to select “unsure” as an
option (p = 0.025). There were no significant differences for the other selections.
Counselors were asked to select from any of the available options summarized in Figure
4 that they felt would better help prepare them for counseling a patient with this indication. A
majority (91.2%, 315/343) felt that more than one resource was needed, with an average of 3
selections per participant.

Figure 4

Resources needed by counselors (n = 1,133)
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Attitudes
As previously stated, participants of both arms were asked if they believed that the
potential benefits of NIPT’s ability to screen for neoplasms/cancer outweigh its potential
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harms, both currently and in the future. Additionally, counselors were asked their opinion as to
whether NIPT companies should report non-validated findings, such as for neoplasms or
cancer. Findings are summarized in Figure 5a and Figure 5b, respectively.

Figure 5a:

Attitudes regarding NIPT’s ability to indicate maternal neoplasms (n = 343)
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Figure 5b:

Attitudes regarding NIPT’s ability to indicate maternal neoplasms (n = 343)
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Labs should NOT report non-validated findings
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A majority of counselors from both arms either agreed or strongly agreed that the
benefits of NIPT’s ability to indicate maternal neoplasms currently outweigh its harms.
Counselors who reported personal experience with an NIPT neoplasm case were more likely to
agree that benefits outweigh the harms both currently and in the future (p = 0.026 and p =
0.043, respectively). There was a significant positive shift of responses on the Likert scale
when asked about the potential future benefits; counselors were more likely to express
agreement in this scenario than in the former (p < 0.001).
About half of all counselors felt that despite these feelings not being validated, NIPT
labs should still report these to providers. Lab and pediatric genetic counselors were less likely
to agree (p = 0.083 and 0.575, respectively), whereas counselors who practiced in prenatal and
cancer settings were more likely to agree with this statement (p = 0.001 and 0.004,
respectively).
DISCUSSION
Three hundred forty-three genetic counselors were surveyed on their awareness,
preferences, and attitudes regarding the ability of NIPT to indicate maternal neoplasms. Despite
the rarity of this indication, our study shows that the majority (95%) of genetic counselors were
aware NIPT results may indicate maternal neoplasms at the time they were surveyed. This
awareness is most likely attributed to the fact that data regarding NIPT’s ability to detect
maternal malignancy was presented at a national genetics conference (ACMG) [14, 15], as well
as published by Bianchi et al. [19] shortly prior to the survey distribution. This is corroborated
by the fact that the majority of participants (58.3%, 200/343) stated that they learned of NIPT’s
ability to indicate maternal neoplasms through a professional conference, peer-reviewed
journal, or discussion forum. However, when asked about “maternal neoplasms,” a specific
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delineation was not made in this survey between malignant/cancerous neoplasms and benign
neoplasms such as fibroids. The world “fibroid” was only mentioned by two participants in the
study, while different variations of “not necessarily cancer” were mentioned 13 times.
However, phrases such as “significant health complications,” “life-saving,” or “cancer” were
mentioned 60 times. Therefore, a conclusion cannot be made as to whether respondents were
aware that NIPT can raise concern for BOTH benign and malignant neoplasms, as opposed to
just malignancy.
Although awareness of NIPT’s ability to indicate maternal cancers was high among all
counselors, and recommendations have been proposed to include the discussion of the
possibility of “maternal or fetal incidental findings” in pre-test counseling [24], only 29% of
prenatal counselors who discuss NIPT report routinely including this statement in their pre-test
counseling, with 44.6% reporting they “rarely” or “never” discuss it. Simply becoming aware
of NIPT’s neoplasm screening ability did not seem to introduce a significant change to
counselors’ pre-test counseling for NIPT (p = 0.154). Rather, a change to pre-test counseling
was observed when counselors instead had encountered this indication first-hand (p < 0.001).
This suggests that these experiences have greatly influenced the way in which these counselors
have chosen to approach pre-test counseling for NIPT.
However, those who have made changes to their pre-test counseling cite inconsistent
methods for communicating this possibility to patients. Most counselors (47.6%, 20/42) said
they now include a vague statement about the possibility of uncovering “unexpected results,”
but some (21.4%, 9/42) will always explicitly mention that neoplasms or cancer can confound
results. Others (7/42, 16.7%) treat the discussion of this on a case-by-case basis, including this
only for patients who have a personal history of caner, are “information-seeking,” or “highly
anxious.” Those who have decided not to discuss this possibility in the pre-test setting cite
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barriers such as a lack of validated data or guidelines for patient management. Only 10% (4/41)
of respondents who elaborated on their choice to not change their pre-test counseling stated that
they do not order NIPT through a lab that performs testing via MPSS. This data shows that
despite large awareness amongst counselors, the discussion of the possibility of “maternal or
fetal incidental findings” in pre-test counseling is not routinely being done even when testing is
being ordered through labs that can indicate this finding, bringing into question if true informed
consent is being obtained at the time of pre-test counseling.
While the possibility of unexpected or rare results is not always addressed in pre-test
counseling, 76.8% of the prenatal counselors surveyed reported that they would disclose results
suspicious for maternal neoplasms to a patient, even if not clearly documented on the test
report. This is despite the fact that approximately half of counselors reported they would feel
“uncomfortable” or “very uncomfortable” counseling this type of indication. Counselors who
support disclosure of results largely cited an ethical obligation to disclose results that may have
significant health implications for their patient. Therefore, it appears that many counselors are
comfortable stepping outside of their comfort zone if they perceive a benefit to their patient.
Additionally, 69.1% of counselors across specialties felt that NIPT results indicative of
maternal neoplasms should be both documented on the test report and discussed by the lab
director in order to better understand the implications of the results and to justify further
workup. Many individuals alluded to how this situation is not much different than incidental
findings being uncovered with other genetic tests. As one participant stated, “They are
incidental findings, not exactly the same but similar to the ones we encounter with [Whole
Exome Sequencing]. These NIPT findings shouldn’t be ignored any more than the WES
incidental findings.”
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Conversely, counselors who did not support disclosure of these results, and who did not
believe these results should be reported or documented, consistently cited the overall lack of
data and guidelines as barriers. One participant summarized it as “looking in the dark without a
flashlight.” Given the paucity of available information about the sensitivity, specificity, or
positive predictive value of NIPT’s ability to screen for maternal neoplasms, it is not
unreasonable for counselors to have these reservations. Furthermore, unlike medically
actionable incidental findings uncovered from other medical tests, the need for medical action
following abnormal NIPT results indicating maternal neoplasm has not yet been clearly
defined. It is also uncertain what, if any, appropriate clinical evaluation or follow-up might be
in these situations. This was further evidenced by the wide variation in recommendations or
referrals that were suggested by the surveyed group when counseling a case for which NIPT
results indicate maternal neoplasm. A majority (86%) would recommend more than one
referral, and the most common selection made was for a referral to oncology. However, as
Bettegowda [6] and Bianchi [19] found, it is possible that the neoplasm generating cfDNA is
not yet to a stage where it would be detected by standard imaging. On average, detection of
malignancy occurred approximately 5 months (range: 3 weeks – 39 weeks) after having an
abnormal NIPT result in Bianchi’s cohort [19]. Additionally, the neoplasm may not even be
malignant and require cancer treatment, as is the case for uterine fibroids. Some counselors in
this cohort as well as in prior literature [26] suggested that whole-body MRI’s be offered to
these patients. But without documentation of NIPT results justifying this workup, it is unlikely
that insurance companies will cover these tests, some of which are contraindicated during
pregnancy. This is without considering the fact that, as of April 2016, whole-body MRIs do not
yet exist as a CPT code and are not recognized as a billable test by insurance companies [27].
And since not all malignancies are immediately detected following NIPT results, the timing and
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duration of performing this workup is unclear. These frustrations were frequently cited by
counselors in this cohort.
Despite all of these limitations, 44% (152/343) of all counselors surveyed believed that
the benefits of NIPT’s ability to indicate maternal neoplasms outweigh its potential harms. This
held particularly true for counselors who had personal experience with this indication (p =
0.026). Additionally, counselors who practiced in prenatal or cancer settings were more likely
to agree that NIPT laboratories should report non-validated data such as neoplasms/cancer (p =
0.001 and p = 0.004, respectively). This implies that those counselors who encountered this
indication first-hand may be more likely to appreciate its utility or have directly observed its
value, despite its clear limitations. It also implies that prenatal and cancer counselors appreciate
knowing more information from the laboratories even when limited.
As the number of high-risk and low-risk women undergoing NIPT expands, it is not
unreasonable to predict that results indicating maternal neoplasms may become more common.
Expanded non-invasive methods evaluating genome-wide copy number variants may also
capture more women with neoplasms of altered chromosomes not routinely analyzed with
traditional NIPT (21, 18, 13, X, and Y). While it can be assumed that the majority of the burden
of pre-test and particularly post-test counseling will fall on prenatal counselors, further workup
may call upon involvement and collaboration between counselors from multiple specialties.
Ultimately, NIPT was not designed to detect maternal neoplasms, or maternal genetic
aberrations in general. However, this is a real possibility of the testing and a majority (80.2%)
of counselors believe that the benefits will outweigh the harms in the future. Currently
however, the inconsistencies observed in pre-test counseling, recommendations for patient
management, and reporting preferences demonstrate a need for national or institutional
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guidelines to establish a standard by which counselors can base their counseling. Ninety-one
percent of counselors in this cohort across all specialties ultimately affirmed that guidelines
were necessary to better prepare for these cases both pre- and post- test, and to make
appropriate recommendations. Additional counselors make a call for more literature and case
reports, as well as discussion and presentations through various platforms, including national
conferences.
Limitations
This study could possibly reflect a skewed population, biased by ascertainment, in
which counselors who were not familiar with this topic may have been dissuaded to participate
in the survey. Additionally, as previously discussed, this survey was distributed shortly
following the annual ACMG conference in 2015, in which this topic was discussed. Those who
attended this conference could have thus been more aware and educated about this possibility,
and more inclined to participate.
Additional limitations included a study design that was not based upon validated
measures. The subgroup that represented counselors with personal experience with a case in
which maternal neoplasms were indicated with NIPT was derived from a question aimed to
assess awareness. This group represented those who selected “I have encountered a case like
this in my personal experience” when asked, “How did you first learn of this possibility?” This
may have inadvertently excluded those who have encountered such a case, but had learned
about this possibility prior to that event. Therefore, this sample (n = 30) may not encompass
everyone who experienced a case like this first-hand. Further limitations to study design
included the exclusion of an explicit definition of “neoplasm,” as previously discussed.
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Future Directions
As evidenced by genetic counselors’ desire for more information, the next most
appropriate step would be to publish more data regarding NIPT’s neoplasm screening ability.
Due to the rarity of these events, collaboration amongst researchers, clinicians, and laboratories
is needed.
As these results have equal implications for OB/GYNs who might encounter them in
clinical practice either with or without access to a genetic counselor, future research might
explore similar factors regarding the awareness, preferences, and attitudes of OB/GYNs.
Governing bodies that produce guidelines such as the American College of Obstetrics and
Gynecology and the National Society of Genetic Counselors may be prompted to create
recommendations for patient counseling and management.
Additionally, exploring patient preferences may provide an interesting view of how to
move forward with developing or later, adapting guidelines. This could include an examination
of the psychosocial effects of receiving incidental findings with such a range of implications,
from a fibroid to a cancer that cannot be detected with imaging.
CONCLUSION
While NIPT results suggestive of maternal neoplasms are thought to be rare, they
present a challenge for clinicians since little direction is currently available to help guide
patient counseling and management. These results have the potential to indicate significant
health implications for the patient, and the majority of counselors in this study felt the
information was beneficial. However, a majority do not feel properly equipped to counsel this
indication due to a lack of data. This study demonstrates a need for collaboration amongst
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clinicians, researchers, and laboratories to publish data, and prompts institutional or national
governing bodies to create guidelines from which clinicians can base their practice.
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APPENDIX
Survey Questions
1. How many total years of experience do you have as a genetic counselor?
a. 0 – 5 years
b. 6 – 10 years
c. 11 – 15 years
d. 16 – 20 years
e. > 20 years
2. How many total years of experience do you have in your current specialty?
a. 0 – 5 years
b. 6 – 10 years
c. 11 – 15 years
d. 16 – 20 years
e. > 20 years
3. In what type of institution do you currently work? [select all that apply]
a. University medical center
b. Private hospital/medical facility
c. Public hospital/medical facility
d. Physician’s private practice
e. Commercial laboratory
f. Other: ___________________
4. In what region do you currently work?
a. Northeast: CT, MA, ME, NH, NY, RI, VT
b. Mid-Atlantic: DE, MD, NJ, PA, VA, WV
c. Southeast: AK, AL, FL, GA, LA, MS, NC, SC, TN
d. Southwest: AZ, CO, NM, OK, TX, UT
e. Midwest: IA, IL, IN, KA, KY, MI, MN, MO, NE, ND, OH, SD, WI
f. West: AK, CA, HI, NV
g. Northwest: ID, MT, OR, WA, WY
h. Other: ___________________
5. Do you currently see patients:
a. Yes
b. No
6. Do you currently counsel patients about non-invasive prenatal testing OR discuss noninvasive prenatal testing with medical providers?
a. Yes
b. No
7. What is your current genetic counseling specialty? [select all that apply]
a. Prenatal
b. Cancer
c. Laboratory/Industry
d. Pediatrics/Medical Genetics
e. Other: ___________________
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PRENATAL ARM
8. For the below section, assume you are counseling a patient for a routine indication for noninvasive prenatal testing (NIPT), such as advanced maternal age (AMA), positive quad
screen, etc. Please select the frequency for which you discuss the following during PRETEST COUNSELING for NIPT:
Always

Most of the time Sometimes Rarely

Never

NIPT can evaluate for fetal sex
Accuracy of NIPT
NIPT may not yield a result
Cell-free DNA originates from the
placenta
Either false negatives or false
positives may occur
Confirmation of a positive NIPT
result warrants further diagnostic
testing, such as CVS or
amniocentesis
Possible reasons for a false
positive result
Possible reasons for a false
negative result
Results may indicate unexpected
or rare conditions in pregnancy or
mother
9. Are you aware that NIPT results have prompted concern for and/or have led to the
diagnosis of maternal neoplasms/cancers in pregnant women? If so, how did you first learn
that NIPT could indicate maternal neoplasms?
a. I was not previously aware that NIPT could indicate maternal neoplasms/cancer
b. I have encountered a case like this in my own clinical experience
c. From a colleague
d. A professional conference, peer-reviewed journal, or discussion forum
e. Popular media, such as an online news article
f. I do not recall
g. Other: ___________________
10. Since becoming aware of NIPT’s ability to indicate maternal neoplasms/cancer, has your
NIPT PRE-TEST counseling changed?
a. Yes, it has greatly changed
b. Yes, it has slightly changed
c. No, it has not changed
11. Please feel free to elaborate. [free response]
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Pregnant patients with abnormal NIPT results indicative of maternal neoplasms/cancers with
chromosomal abnormalities originating from the tumor have been reported. As of June 2015,
concerns for neoplasms/cancer are not documented on the NIPT report, but are verbally
discussed by laboratory directors, or are reported as multiple aneuploidies in some cases.

12. If an NIPT laboratory informed you of a concerning NIPT result indicative of a possible
maternal neoplasm/cancer, but this information was NOT included on the NIPT report,
would you disclose this information to your patient?
a. Yes
b. No
c. Unsure
13. Why or why not? [free response]
14. If an NIPT laboratory informed you of a concerning NIPT result indicative of a possible
maternal neoplasm/cancer, but this information WAS included on the NIPT report, would
you disclose this information to your patient?
a. Yes
b. No
c. Unsure
15. Why or why not? [free response]
16. What further recommendations, options, or referrals would you make, if any? [select all
that apply]
a. No further recommendations
b. Referral to oncology
c. Referral back to OB/GYN or MFM
d. Referral to PCP
e. Referral to medical geneticist
f. Repeat NIPT
g. Perform traditional screening test (FTS, quad)
h. Invasive testing (CVS, amniocentesis)
i. Ultrasound
j. Unsure
k. Other: ___________________
17. How comfortable would you feel counseling a patient about NIPT results indicating
maternal neoplasms/cancer?
a. Very comfortable
b. Comfortable
c. Neutral
d. Uncomfortable
e. Very uncomfortable
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18. How would you prefer for incidental findings of possible maternal neoplasms/cancer to be
reported?
a. Findings should NOT be reported
b. Findings should be discussed by a lab director or lab genetic counselor AND
included on the report
c. Findings should be discussed by a lab director or lab genetic counselor but NOT
included on the report
d. I do not have a preference
e. Unsure
f. Other: __________________
19. Why or why not? [free response]
20. Who should be making the decision as to whether NIPT incidental findings of possible
maternal neoplasms/cancer are reported? [select all that apply]
a. Performing labs
b. Ordering clinicians
c. Patients
d. Institutional or national guidelines
e. Unsure
f. Other: __________________
21. What information do you feel would help better prepare you for these cases?
a. Institutional or national guidelines for reporting, management, and consent
b. Peer-reviewed publications or published case reports
c. More presentations or discussions regarding these cases at national conferences such
as NSGC, ACMG, ACOG, etc.
d. Laboratory-provided data on sensitivity and specificity for neoplasm screening
e. Unsure
f. Other: __________________
Please indicate your level of agreement with the following statements:
22. At this time, I believe the potential benefits of NIPT’s ability to screen for
neoplasms/cancer outweigh the potential for harm
a. Strongly Agree
b. Agree
c. Neutral
d. Disagree
e. Strongly Disagree
23. In the future, I believe the potential benefits of NIPT’s ability to screen for
neoplasms/cancer outweigh the potential for harm
a. Strongly Agree
b. Agree
c. Neutral
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d. Disagree
e. Strongly Disagree
24. NIPT companies should not report non-validated findings, such as maternal
neoplasms/cancer
a. Strongly Agree
b. Agree
c. Neutral
d. Disagree
e. Strongly Disagree
NON-PRENATAL ARM
NIPT (noninvasive prenatal testing) is a blood test that analyzes cell-free fetal DNA in maternal
circulation. The test is offered to women during pregnancy and is primarily used to screen for
fetal aneuploidies such as trisomy 21, trisomy 18, and trisomy 13. Pregnant patients with
abnormal NIPT results indicative of maternal neoplasms or cancers with chromosomal
abnormalities originating from the tumor have been reported. As of June 2015, concerns for
neoplasms/cancers are not documented on NIPT reports, but are verbally reported by laboratory
directors, or are reported as multiple aneuploidies in some cases.
8. Were you previously aware that NIPT results have prompted concern for and/or have led to
the diagnosis of maternal neoplasms/cancers in pregnant women? If so, how did you first
learn that NIPT could indicate maternal neoplasms?
a. I was not previously aware that NIPT could indicate maternal neoplasms/cancer
b. I have encountered a case like this in my own clinical experience
c. From a colleague
d. A professional conference, peer-reviewed journal, or discussion forum
e. Popular media, such as an online news article
f. I do not recall
g. Other: ___________________
9. How would you prefer for incidental findings of possible maternal neoplasms/cancer to be
reported?
a. Findings should NOT be reported
b. Findings should be discussed by a lab director or lab genetic counselor AND
included on the report
c. Findings should be discussed by a lab director or lab genetic counselor but NOT
included on the report
d. I do not have a preference
e. Unsure
f. Other: __________________
10. Why or why not? [free response]
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11. Who should be making the decision as to whether NIPT incidental findings of possible
maternal neoplasms/cancer are reported? [select all that apply]
a. Performing labs
b. Ordering clinicians
c. Patients
d. Institutional or national guidelines
e. Unsure
f. Other: __________________
12. What information do you feel would help better prepare you for these cases?
a. Institutional or national guidelines for reporting, management, and consent
b. Peer-reviewed publications or published case reports
c. More presentations or discussions regarding these cases at national conferences such
as NSGC, ACMG, ACOG, etc.
d. Laboratory-provided data on sensitivity and specificity for neoplasm screening
e. Unsure
f. Other: __________________
Please indicate your level of agreement with the following statements:
13. At this time, I believe the potential benefits of NIPT’s ability to screen for
neoplasms/cancer outweigh the potential for harm
a. Strongly Agree
b. Agree
c. Neutral
d. Disagree
e. Strongly Disagree
14. In the future, I believe the potential benefits of NIPT’s ability to screen for
neoplasms/cancer outweigh the potential for harm
a. Strongly Agree
b. Agree
c. Neutral
d. Disagree
e. Strongly Disagree
15. NIPT companies should not report non-validated findings, such as maternal
neoplasms/cancer
a. Strongly Agree
b. Agree
c. Neutral
d. Disagree
e. Strongly Disagree
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